



Clinical trial results:

Dose determination of Taxotere®, Eloxatin® and Xeloda® (TEX) in combination with Herpectin® as first line treatment to patients with HER2-positive non-resectable esophagus, cardia or gastric cancer

Summary

EudraCT number	2010-021016-41
Trial protocol	DK
Global end of trial date	01 June 2015

Results information

Result version number	v1 (current)
This version publication date	19 March 2021
First version publication date	19 March 2021

Trial information

Trial identification

Sponsor protocol code	10.05
-----------------------	-------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Odense University Hospital
Sponsor organisation address	J. B. Winsløws Vej 2, entrance 140, basement, Odense C, Denmark, 5000
Public contact	Ida Coordt Elle, Odense University Hospital, +45 29335922, ida.coordt.elle@rsyd.dk
Scientific contact	Per Pfeiffer, Odense University Hospital, +45 26283844, per.pfeiffer@rsyd.dk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 March 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	01 June 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine maximum tolerable dose (MTD) for the combination regime TEX (docetaxel, oxaliplatin and capecitabine) + trastuzumab and to evaluate the toxicity

Protection of trial subjects:

Administration of pre-medication to minimize adverse events.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	21 March 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Denmark: 17
Worldwide total number of subjects	17
EEA total number of subjects	17

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	10
From 65 to 84 years	7
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

March 2011-November 2014.

Pre-assignment

Screening details:

Patients with histologically confirmed ECV adenocarcinoma, non-resectable or metastatic disease.
Tumor tissue must be HER2 positive.

Period 1

Period 1 title	Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Experimental
-----------	--------------

Arm description:

Six treatments with Her-TEX followed by Trastuzumab monotherapy until disease progression.

Arm type	Experimental
Investigational medicinal product name	Trastuzumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution and suspension for suspension for injection in pre-filled syringe
Routes of administration	Intravenous use

Dosage and administration details:

8 mg/kg i.v. over 90 minutes on day 1, hereafter 6 mg/kg i.v. over 30 minutes every three weeks.

Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Docetaxel 42-60 mg/kg (70-100% dose) i.v. over 60 minutes on day 1 every three weeks.

Investigational medicinal product name	Oxaliplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Oxaliplatin 100 mg/m² i.v. over 30 minutes on day 1 every three weeks.

Investigational medicinal product name	Capecitabin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

625 mg/m²/day twice a day (1250 mg/m² daily) continuously.

Number of subjects in period 1	Experimental
Started	17
Completed	17

Baseline characteristics

Reporting groups

Reporting group title	Trial
-----------------------	-------

Reporting group description: -

Reporting group values	Trial	Total	
Number of subjects	17	17	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	10	10	
From 65-84 years	7	7	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	5	5	
Male	12	12	

Subject analysis sets

Subject analysis set title	Patients
----------------------------	----------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Full analysis of all patients included.

Reporting group values	Patients		
Number of subjects	17		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	10		
From 65-84 years	7		
85 years and over	0		

Gender categorical			
Units: Subjects			
Female	5		
Male	12		

End points

End points reporting groups

Reporting group title	Experimental
Reporting group description: Six treatments with Her-TEX followed by Trastuzumab monotherapy until disease progression.	
Subject analysis set title	Patients
Subject analysis set type	Full analysis
Subject analysis set description: Full analysis of all patients included.	

Primary: Dose establishment

End point title	Dose establishment ^[1]
End point description: Dose level escalation of Docetaxel: 42 - 60 mg/m2. Dose level 3 was never included. Dose level 2 is the maximal tolerable dose.	
End point type	Primary
End point timeframe: 24 months	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: It makes no sense to perform a statistical analysis on this type of end point. It is based on doctors' evaluation of MTD.	

End point values	Experimental	Patients		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	17	17		
Units: dose level	2	2		

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free survival

End point title	Progression-free survival
End point description: Five patients did not progress during the five year time frame. Four are still alive as of March 2021.	
End point type	Secondary
End point timeframe: 60 months	

End point values	Experimental	Patients		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	17	17		
Units: months				
median (confidence interval 95%)	10 (3 to 60)	10 (3 to 60)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Last treatment+30 days

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

Reporting groups

Reporting group title	Patients
-----------------------	----------

Reporting group description: -

Serious adverse events	Patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 17 (76.47%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Edema			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Febrile infection			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	3 / 17 (17.65%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		

Vomiting			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Sepsis			
subjects affected / exposed	2 / 17 (11.76%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Abscess			
subjects affected / exposed	1 / 17 (5.88%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 17 (100.00%)		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	5 / 17 (29.41%)		
occurrences (all)	5		
Nail toxicity			

subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	6 / 17 (35.29%)		
occurrences (all)	6		
Nausea			
subjects affected / exposed	7 / 17 (41.18%)		
occurrences (all)	7		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported